Mitogen-activated protein kinase 3 (MAPK3) and human epidermal growth factor receptor 2 (HER2) on recurrent intracranial meningiomas: a case report

Abstract

Introduction. Meningiomas accounts for one-third of all adult central nervous system tumors and by far the most common primary intracranial tumor in adults. Despite their high prevalence, it remains challenging to predict their biological and clinical behavior. To date, it has been accepted that the extent of surgical resection and histological grade are the most reliable factors to predict the recurrence of meningiomas. HER2 and MAPK3 represent a well-known prognostic factor in various tumors, however only a few studies on the relationship between meningioma recurrence, HER2, and MAPK3 expression. This report presents additional data that support the relationship between the expression HER2 and MAPK3 with recurrent of meningioma.Case: We report 39 years-old-female with recurrent meningioma. The patient had tumor removal a year ago. After the first resection, the tumor demonstrated rapid growth with significant invasion to neighboring dural tissue and brain parenchyma, which resulted in impaired brain function and intracranial hypertension manifested as severe headache, vomiting, and coma. Histopathological examination confirms a malignant meningioma (WHO grade I). The patient had the second craniotomy for tumor removal, and we performed immunohistochemical staining. The result was positive for HER2 and MAPK3Conclusion: HER2 and MAPK3 might be a reliable predictor of recurrent meningiomas.Â

Meningioma pada akseptor kontrasepsi hormonal: laporan kasus

“…pada pasien Unit Rawat Jalan RSCM dari Januari 2014 hingga Desember 2015 didapatkan hasil dari 65 sampel perempuan seluruhnya sedang menggunakan atau pernah menggunakan kontrasepsi hormonal. 3 Ada beberapa pernyataan yang dikemukakan oleh Supartoto dkk. mengenai keterkaitan kontrasepsi hormonal eksogen dengan risiko meningioma.…”